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Cardiac Catheter Reuse rn An Era of Reform:
Cost-Eciency and Regulatory Policy in the Face of Scientic Uncertainty
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Introduction
Cardiac catheters have become an essential element of current cardiovas-
cular practice with several hundred thousand used each year in both diagnos-
tic and angioplasty procedures. Uke many other disposable devices they are
also increasingly being reused as hospitals attempt to cut costs.' The general
progression of device reuse seems to follow rather directly the rise in the ex-
pense of medical equipment and procedures. For example, in 1976, only 14%
of United States' hospitals reported reusing single-use devices, while in 1982,
90% of hospitals admitted practicing reuse.2 As for the government's regulation
of such reuse, 1981 saw the FDA issuing guidelines practically proscribing the
reuse of catheters when their average cost was only $10-$25.~ Even as late as
1987, however, only 2.4 full-time FDA employees and $19,000 were dedicated
to monitoring the reuse of nondurable devices.4 The General Accounting Oce
concluded that the FDA knew of less than 1% of medical device problems oc-
curring in hospitals.5 On the heels of the longstanding debate about the reuse
of hemodialyzers and the Safe Medical Devices Act of 1990 and 1992 Medical
Device Amendments, it appears as if the FDA is more receptive to tightening
regulatory control over medical device reuse.
This paper will address the increasing cost-containment incentives to reuse
cardiac catheters, countervailing scientic uncertainty about attendant health
risks and nally, several proposals for a regulatory scheme addressed at both
manufacturers and hospitals to better ensure the safety and ecacy of previously
designated single use only devices.
2I. Cost Containment Incentives to Reuse Catheters
Cardiac catheters serve as an excellent model for predicting what the practice
of reuse may do for cost containment programs, since they are both relatively
expensive and frequently used.6 Catheters are also one of the few devices which
have several manufacturers currently in competition for an ever cost-conscious
health care market. Recent estimates suggest that millions of dollars could be
saved by hospitals each year if each catheter were reused only once. But there
is also a healthy dose of skepticism surrounding reuse, because in an time when
the majority of hospital patients are becoming capitation fee patients7, cutting
millions of dollars in costs means one thing for the hospital -prot. Cost-cutting
motives on the part of Medicare and other third party payors have also been
inuential, leading to increased hemodialyzer reuse in the mid1980s. In 1981,
90% of dialyzers were single-use, while now over 70% are reused, up to 12 times.8
Statistics obtained from the Brigham and Women's Hospital in Boston show
that the cost savings for one reuse of the more frequently ordered cardiac
catheters would be $175,500, after expenses for a sterilization technician and
resterilizing materials.9 If Brigham and Women's were to follow current trends
of reuse (use up to 5 times), savings could be upwards of $1 million dollars
annually. When one considers that more than 300,000 angloplasty procedures
were performed in the United States in 1990, the potential cost savings appear
to be magnanimous.'0
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Cost savings to hospitals and patients, one of the primary goals of reuse,
should not be mis-characterized as a simple game of subtracting the number of
units no longer required to be purchased. There are many costs associated with
reuse including, but not limited to increased labor costs, supply costs, machine
time for cleaning, repackaging, storage, and quality assurance documentation.11
These costs when considered along with the cost of administrative red tape and
further scientic studies may greatly minimize the benets currently foreseen.
Reuse is not desirable from the standpoint of most manufacturers. They
argue that while cost containment is a noble goal, and the possibility of reusing
products may merit further examination, some devices simply cannot survive
more than one use, and in the face of scientic uncertainty should not see more
than one use. From a cost-containment perspective, manufacturers also warn
that widespread reuse may drive up prices as companies anticipate lower sales
due to multiple uses. Competition will become driven by the tensile strength of
the catheter (in many cases already overdesigned), how many resterilizations it
can withstand, accompanying diagnostic software, or sterilization contracts to
an outlying facility to reduce hospital liability for sterilization mishaps.
One glaring exception appears to be Minntech Corporation which has de-
signed a PTCA reprocessing machine which was launched overseas in August,1993
and for which the company is now approval in the United States. Minntech
catheters are identied during reprocessing with a serial number attached to
the device's proximal end so users can keep track of the number of
4
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reuses, with the company recommending no more than ve uses. Minntech
estimates that should catheter reuse in the United States and other countries
eventually approximate that of Europe, the market could be worth about $27
million.'2
To prevent reuse, some manufacturers and health ocials have suggested
marketing devices that will not survive more than one use. This approach has
several drawbacks, most notably the need for new pre-market notication ings
(51 0(k)s) or perhaps pre-market approval applications. Development costs to
the manufacturer would likely be substantial and result in a more expensive
product for the consumer. Furthermore, there is the threat that physicians
may simply tinker with these modied devices to attempt their reuse, perhaps
injuring or killing patients.
Finally, it is unclear what the legal ramications may be if the government
or institutions begin mandating device reuse to achieve cost-containment bene-
ts. In the 1986 case, Wickline v. State of California'3, the court attempted to
determine the legal responsibility that a third party payor has for harm caused
to a patient when a cost containment program is applied in a manner which
is alleged to have aected the implementation of the treating physician's med-
ical judgment.'4 The court held that as long as an individual physician could
overrule the institution's cost-containment policy through some sort of review
process, the third party payor should not be held liable for patient injury. In
the realm of device reuse, however, chances are that any one physician will not
know
5
5whether the catheter she is using has been recycled or is new. The stage
for this type of suit has already been set with HCFA threatening to withhold
reimbursement from hospitals who don't reuse hemodialyzers. Somewhat incon-
sistent with their cost-containment mandate, however, when they do reimburse
for these products The amount paid is the same whether it is a new device used
or one used for the tenth time.
U. Scientic Uncertainty and Health Risks Associated
with Reuse
One concern of biomedical engineers and central processing departments
involves the potential for inadequate sterilization, resulting in infection. EtO
(ethylene oxide) sterilization is the most common method of industrial and
hospital catheter sterilization, but it is incapable of sterilizing proteins such as
blood and organic debris that may be left behind in the catheter after use. As
a result, if the catheter is improperly cleaned before sterilization, those proteins
can then be passed to the next patient upon reuse. In addition, EtO sterilization
is controversial given its toxicity if residual particles are found after improper
aeration. Given the possibility of improper implementation and toxicity, there
is a growing fear among the scientic community that hospitals will regard a
given reprocessing method as acceptable until adverse reactions are reported,
and that methods with more dangerous properties may become more popular.'5
Most sterilization methods are approved and detailed by industrial steriliza-
tion companies, but there are several problems unique to in-hospital
6
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sterilization that are of some concern to the public safety, not the least of
which include the threat of AIDS or hepatitis B transmission. First, hospi-
tals are not required to validate any product they process; many merely rely
upon information they receive from either the sterilant producer, the product
manufacturer or both.'6 Secondly, most hospitals do not have the luxury of
sterilizing one product per machine and often vary their loads in both content
and packaging. An Ohio study comparing industrial and hospital reuse process-
ing techniques demonstrated that hospital sterilization necessitated extending
device aeration time by 46 hours, and exposure time by some 75 minutes.'7 Sug-
gestions for hospitals also included implementation of dedicated loading, using
biological monitors in each load, post-sterilization microscopic inspection and
increased glove use.'8 Finally, there is concern regarding the quality of steriliza-
tion technicians. The qualications for a laboratory aide in the cardiac catheter
lab at many hospitals require only the ability to read, write, and follow verbal
and written instructions, and a high school diploma. Most knowledge required
to perform these tasks will be acquired through on the job training, but the 2-3
is sheet of detailed instructions for each catheter could be confusing to those
with a scientic background.
In addition to concerns about sterilization, the physical integrity of catheters
and angioplasty balloons in particular is uncertain upon reuse. A British study
in the early 1980s revealed that while 8% of balloon angioplasty devices experi-
enced a rupture after the rst use, nearly 62% had ruptured after
7
74O4v4-~
the fourth use. At that time British hospitals were known to reuse the
devices as many as 18 times. Most importantly, reuse demonstrated a reduced
life span of the device in that it was capable of performing less than one half the
average ination/deation cycles that one could attain with a new catheter.20
While rupture is easily detectable, a recent study at the University of Wis-
consin examined more subtle problems with the physical, electrical and me-
chanical integrity of Webster/Manseld deectable catheters after reuse.2' The
primary reason for catheter rejection in the study was found to be glue separa-
tion, short of causing the device to fail, from the tip electrode, allowing glue to
be released into the bloodstream and blood to collect in the space left behind
in the catheter.22 This deterioration precluded proper cleansing, rendering the
catheter unt for further use. On the basis of their ndings, the researchers
at Wisconsin suggested that these catheters be used no more than ve times.~
Apart from glue separation, no other major failures of the device occurred in-
dicating that the integrity of the Manseld/Webster ablation catheter performs
rather well under reuse conditions. However, the study was limited to one spe-
cic catheter, and eorts must be made to study the safety and ecacy of all
before a change in FDA policy is warranted to further permit reuse. Currently,
the Wisconsin and similar studies appear to be garnering attention and the test-
ing methods are being employed at hospitals such as the Brigham and Women's
Hospital in Boston. Brigham and Women's hospital is unique perhaps, in its
eorts to implement stringent continuous quality improvement measures
8
8including semi-annual electron microscopy tests, detailed reuse documenta-
tion, and loose particle testing. Indications of inadequate reprocessing will cause
the reuse program to cease and the procedures reevaluated.24
Due to the lack of comprehensive catheter studies involving comparison test-
ing among sterilants, aeration times, and various brand products, and given the
range of possible deleterious health eects; further regulation of catheter reuse
must be implemented to examine whether the current level of uncertainty about
the scientic desirability of reuse can be minimized. No one knows what the
possible health risks of catheter reuse could entail, as studies examining patient
reactions have been limited to fever, chills and hypotension.25
While some argue that science should drive regulatory policy, rather than
the reverse, both sides have demonstrated an unwillingness to pursue the matter
to the detriment of the patient.
III. Regulatory Policy
A. Current
Despite growing cries of cost-containment and the fear associated with sci-
entic uncertainty, the current regulatory stance of the FDA regarding device
reuse is quite limited. In fact, the only device currently regulated is the dialysis
hemodialyzer, which is vastly dierent than a cardiac catheter. Hemodialyzer
reuse is only authorized for the same patient in order to eliminate the risk of
infectious disease transmission. Also the population of hemodialyzer patients Is
9
9much smaller than the number requiring catheterization procedures each
year. Moreover, there is no evidence that a reused catheter can meet the same
standards of a rst time use, whereas reused hemodialyzers have been shown to
be more eective for many patients. Finally, regulations promulgated under the
guidance of HCFA stated that information given to patients using hemodialyz-
ers should include the risks and benets of reuse, while those receiving reused
catheters are not notied 26
Aside from the formal rulemaking involved with the hemodialyzer, the cur-
rent means of handling reuse problems is limited to the Medical Device Reports
(MDR) and labeling. In the past several months, the MDR system has un-
dergone recent changes which could eect institutional reuse policies.27 The
institution of Section H of new reporting form 3500A, to be completed by de-
vice manufacturers, now requires a designation that the adverse event involved
the initial use or reuse of a device, which should improve the quantity and
quality of reuse data available to the FDA.~ Furthermore, user facilities will be
required to provide similar information in another section of the form, perhaps
inducing hospitals without explicit reuse protocols to develop them.29 The in-
creased attention now paid to reuse through these forms, and as evidenced by
FDA responses to comments in the Federal Register suggest that the agency has
recognized that in the past inadequate provisions have been made for collecting
and correlating all salient information to determine and identify the root cause
of, and all factors contributing to adverse events and the implications of reuse
as

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10one of those factors.30 Even under this new system, user facilities need only
report deaths to the FDA, with all other events solely referred to the manufac-
turer upon receiving information or otherwise becoming aware that a device has
caused signicant harm.3'
Follow-up letters were sent to the manufacturer indicating that the frequency
and severity of this event would be periodically monitored to determine if other
action is necessary.32 This phrase appears in almost every MDR report, yet
there is no indication in FDA guidelines or reports as to how often follow up is
conducted or if it has ever revealed further violations. One senses that follow
up is rare given the reluctance of the FDA to strictly monitor the device realm,
and the general lack of resources to adequately monitor changes in sterilization
procedures or hospital protocols.
Recent MDR reports involving cardiac catheters include reports of EtO ster-
ilization weakening adhesive bonds allowing the catheter to stretch and bend
abnormally.33 The catheter had been EtO processed 3 times by the hospital
and the laboratory sta then noticed a wire outside the catheter. Warnings
issued to C.R. Bard in 1992-3 revolved around incidences of reused Peripheral
Transluminal Angioplasty Catheters' (PTCA) tips breaking o inside patients,
at least one of which was unrecoverable. This reuse occurred despite explicit
warnings on the label reading, this catheter is for one time use only; do not
reuse or resterilize for any reason.34 Moreover, the catheter had been used for
the dilatation of a cystic duct, not an indicated use of the product.
11
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Along with MDRs, labeling requirements imposed upon manufacturers by
the FDA have been only marginally eective, although changes are evident and
do show promise for improvement. In 1989, the FDA released manufacturer
guidelines for medical devices regarding sterile device labeling.35 These guide-
lines recommend the labeling of any changes in the physical characteristics of the
device that may result from reprocessing which aect its safety, eectiveness, or
performance; and limit on the number of times resterilization and reuse can be
done without aecting the safety or eectiveness of the device.'<~' While rec-
ognizing that some manufacturers include labeling to advise against reuse, the
FDA suggests that where reuse is common practice, manufacturers should pro-
vide information about resterilization techniques anyway.37 In fact, the agency
has decided that some devices that have been marketed and labeled for single
use will no longer be generally acceptable to the agency, while others will be
required to supplant their labels with a warning against reuse?8
Hemodialyzer manufacturers, for instance, have been called upon by both
the FDA and Congress through agency guidelines to justify their single use
only labels, and it is not farfetched that the same scrutiny may soon fall upon
the catheter industry.39 This increased pressure will require manufacturers to
either provide scientic data on eective sterilization methods or prove that the
item cannot be reused in order to maintain their labeling status. Data will be
compiled both through the 5 10(k) process and via heightened surveillance and
regulatory oversight of Ithe manufacturer's] customers' practices.
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12The Health Industry Manufacturers Association (HIMA) believes that reuse
concerns should be reviewed by an expert panel before single use only labeling
is prohibited to ensure consensus on appropriate methods of safe and eec-
tive reuse.41 HIMA said that it will be dicult to give adequate directions
to users since so many dierent sterilization modes are used by hospitals. ~
The organization has even threatened to challenge the FDA's legal authority
to make the guideline binding, and individual companies have considered suing
as well fearing further liability with respect to labeling instructions. Recent
FDA statements, however, seem to signal a move towards stricter monitoring of
device reuse and formal regulations could be forthcoming. One such indication
is the FDA's shift from merely encouraging manufacturers to eliminate single
use labeling, to requesting the submission of detailed plans for re-labeling.
Hospitals would likely welcome more labeling information as they are con-
stantly requesting guidelines or instructions for product reuse. Not only do
hospitals wish to limit their legal liability, but more hospitals are seeking to
develop stringent in-house protocols as part of continuous quality improvement
programs. Under current guidelines prohibiting manufacturers from giving spe-
cic advice unless a particular sterilization method has been validated, hospitals
are left to trial and error methods of reuse processing.
B. Proposals for Future Regulatory Action
While HIMA and unocial statements by the FDA have long warned that
13
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if you reuse a disposable medical device, you bear responsibility for if safety
and eectiveness, there have been no cases in which a hospital or physician has
been prosecuted, reprimanded, or even warned on record as being a remanu-
facturer.~' While it is true that some large hospitals are developing detailed
protocols for reuse without being labeled manufacturers, many simply will not
force regulatory-type controls upon themselves unless the federal government
clearly designates them a manufacturer.
One reason for mandating manufacturer status for hospitals reusing dispos-
able devices is to foster further development of written reuse protocols and
better reuse documentation. A 1987 survey of all Canadian hospitals showed
that 86% of those hospitals with more than 200 beds reused single use only de-
vices regularly, with 20% admitting reuse of disposable catheters. Despite this
high incidence of reuse, only 38% of those regularly reusing disposable devices
had written reuse or sterilization procedures, and only 32% had mechanisms
in place to determine the number of times a device had been used. Perhaps if
hospitals attained manufacturer status, these statistics and comparable ones in
the United States would show a marked increase in quality assurance programs
and reuse documentation. In addition to general improvement of hospital reuse
protocols, once a hospital or physician is deemed a manufacturer for reusing
disposable devices, it would enable the government to levy civil penalties of up
to $15,000 per violation or up to $1 million in any given proceeding, and man-
date adherence to good manufacturing practices (GMPs) ~ Adherence to GMPs
would require
14
14simulated use testing, where practical, upon nished devices to assure that
device specications are met and sterilization is being properly completed.~
The issue of how to bring hospitals or physicians within the denition of
manufacturer is not dicult. First, courts have been reluctant to read any term
in the Food, Drug and Cosmetic Act narrowly given its broad public mandate to
protect the health and safety of the citizenry. Secondly, the term manufacturer
already has been interpreted within the GMP regulations to include assigners,
contract sterilizers, specication developers and initial distributors of imported
devices, - and the list does not appear to be exhaustive.47 Other issues associated
with manufacturer status, however, are more intractable. For instance, if GMPs
are imposed upon hospitals, compliance reviews by the FDA would be nearly
impossible given the limited resources of the agency. Furthermore, JCAHO and
state medical associations simply cannot be relied upon to conduct these reviews
due to bias, and the omnipresent fear that by shooting one of their own they,
too, will become targets.
A more manageable solution would be the imposition of manufacturer sta-
tus coordinated with a modied GMP standard requiring hospitals to submit
detailed reuse protocols, reports of all adverse events regardless of their severity,
and immediate notication of any changes in sterilization or reuse practice. A
necessary accompaniment would be prompt FDA response to adverse events,
which could perhaps be delegated to state health agencies on an as needed ba-
sis. The Brigham and Women's Hospital in Boston, MA sets a good example
for other
15
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major health care institutions by requiring that any product for which sta
wish to approve reuse, a proposal must be submitted and approved by the Prod-
uct Standardization Committee who will issue a proper protocol with supporting
documentation to be kept on le in the Department of Clinical Engineering.~
While a bit more radical, another solution to the reuse dilemma would be to
change the Food Drug and Cosmetic Act or its interpretation to designate that
a reused single-use device is per se excluded from being a substantial equivalent
of the original device. Substantial equivalence is currently dened in terms of
safety and eectiveness, but is met if a product can demonstrate that it has the
same intended use and same technological characteristics as a pre-Amendment
device.49 This new exclusion should require the reused device to be tested under
a pre-market approval (PMA) system as a class III device leading to the clinical
trials not yet conducted under the present system. However, if this is too
taxing on the FDA and hospitals, at the very least, additional studies should be
required to properly classify such devices as Class II with special controlsY~ A
statutory amendnient might not even be required, with a regulation sucing.
The FDA could merely state that unless the material integrity of the device
can be proven to be as safe as eective as when used the rst time, it fails to
meet the substantial equivalence denition. These changes would be consistent
with the legislative history of the Medical Device Amendments of 1976 which
states that the purpose is to encourage the research and development of medical
devices, but also to be sure that the FDA has proper authority to regulate that
process so that
16
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Americans are not put at risk from the use of unsafe and ineective medical
51
devices.
The primary problem with the substantial equivalence approach is the
additional time and information necessary for premarket approval given the
FDA's belief that, premarket clearance or approval generally should only be
necessary for those changes that require physical alteration of the device that
could signicantly aect its safety or eectiveness.52 The FDA much prefers
510(k) reviews for medical devices in order to save time and paperwork. In
fact expedited 510(k) review was promised to device manufacturers ling before
November 1, 1992?~ Given that between 1976 and 1983 more than 3,000 510(k)s
were submitted for cardiovascular devices, the chance that an inferior product
unable to withstand reuse is on the market seems signcant?~ New hybrid 5
L0(k)s may be of some help in preventing new products from being reused, but
are of little help for those already being reused in the market.
A third term in the Food Drug and Cosmetic Act which could be changed to
aord more control over reused catheters and other devices is intended use. Now
dened as the, objective intent of the persons legally responsible for the labeling
of the devices, intended use can be demonstrated if, with the knowledge of such
persons or their representatives, Ian article isi oered and used for a purpose
for which it is neither labeled nor advertised.55 Tightening up this denition to
prevent manufacturers from being held liable for the unique and unauthorized
actions of a particular facility may be a useful deterrent to some
17
17reuse.
The issue here is with whom lies the right to establish intended uses for a
product, and how best to avoid patient deception when reused devices are used
upon them. Unlike drugs where a doctor may use an approved drug for an
unapproved use given the longstanding FDA position that it is not the business
of the FDA to encroach upon the practice of medicine or pharmacy, not all
or even many doctors are trained in biomedical engineering?' Even support
for the pharmacy exception has been waning as the practice of pharmacy has
changed in the past several decades. In Retkwa v. Orentreich57, a physician
recompounded a liquid silicone compound for injections to alleviate a particular
disease and the court held substance was to be considered a new device and
thus placed in Class III, without premarket approval. As a result, the product
was found to be adulterated and held for sale within the meaning of the Food
Drug and Cosmetic Act?8
A nal option, perhaps best utilized in conjunction with one or more of the
aforementioned proposals, is to pave the way for manufacturers to sue hospitals
and physicians for patent infringement when they reuse a device. Mallindirndk
Inc. v. Medipart. Inc.59. decided in 1992 started the debate by stating that
a buyer could be prohibited from reusing a patented single-use only medical
device if the manufacturer's restriction was reasonably within the patent grant
and not just for anticompetitive reasons. Mallinckrodt, the manufacturer sued
a servicing company for processing the devices for reuse.
18
18The benet of using the patent law to deter reuse of catheters is that the fed-
eral government's involvement would be minimized, limited only to the patent
grant, leaving the enforcement mechanism to disgruntled manufacturers. It
is unclear whether manufacturers will take advantage of this option, however,
knowing that they may lose a signicant part of their market as a result of such
suits. Furthermore, the threat of patent suits may lead to a decline in voluntary
reporting of reuse at many hospitals or the quality of MDRs.
Conclusion
Cardiac catheter reuse for both diagnostic and angioplasty procedures could
provide nancial breaks to hospitals, although no one is sure as to how much will
be saved long-term. The potential costs associated with injured patients and
public scandal in the face of tragedy, however, may well supersede those cost-
containment benets. Comprehensive scientic studies have not been conducted
and despite nearly two decades of medical device regulation, the issue of reuse
lingers in a regulatory void. If reuse is not addressed head-on by the medical
and FDA communities, it is likely that if and when a medical disaster occurs,
an ill-planned, overly restrictive legislative response will be forthcoming. By no
means should reuse be prohibited, but the unwitting patient on the operating
table deserves to know that the catheter on the tray, while used nine times
before, is safe, eective, and under the watchful eye of the FDA.
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24Table A | CARDIAC LAB CATHETERS: Medical Devices - January 25,
1993 Number of Orders
Devices Now If
Reused
Unit
Saved
Unit
Price
Savings
Radio Ablation Cath 100 30 70 $750 52,500
Staiford Bioptones reused | 0
Millar Catheters reused ||- 0
Pacemaker Kits 2 1 1 $7000 7,000
Open PTCA Balloons 0 0 1 $715 715
Open DVI Cutting 0 0 1 $1,175 1,175
Quadpolar Catheters 480 150 330 $230 75,900
Tripolar Catheters 145 40 105 $215 22,575
Hexapolar Catheters 75 25 50 $255 12,750
Octapolar Catheters 20 7 13 $255 3,315
Decapolar Catheters 75 25 50 $255 12,750
Dynamic Tip Cath 20 6 14 $425 5,950
Special Design Cath 10 3 7 $270 1,890
Open Lumen Cath 10 3 7 $255 1,785
Manseld/Webster
#120059
5 2 3 $400 1,200
#120006 5 2 3 $450 1,350
#120010 5 2 3 $450 1,350
1120003 5 2 3 $450 1,350
#140020 5 2 3 $485 1,455
1120000 5 2 3 $430 1,290
1160068 5 2 3 $200 600
#160073 5 2 3 $200 600
TOTALS: 673 $14,865 207,500
Reusable Savings:
Expenses: 1. Manpower.50 FTE 2. Supplies
- 14,000
- 18,000
Estimated Total Savings
$175,500
25